Gain Therapeutics (NASDAQ:GANX) Stock Rating Reaffirmed by HC Wainwright

HC Wainwright reiterated their buy rating on shares of Gain Therapeutics (NASDAQ:GANX) in a report released on Thursday morning, Benzinga reports. The brokerage currently has a $8.00 price objective on the stock.

Other equities research analysts also recently issued reports about the company. Oppenheimer reaffirmed an outperform rating and set a $9.00 price target on shares of Gain Therapeutics in a report on Tuesday, April 23rd. Chardan Capital reaffirmed a buy rating and set a $6.00 price target on shares of Gain Therapeutics in a report on Wednesday, March 27th.

Gain Therapeutics Stock Up 13.3 %

GANX stock opened at $1.36 on Thursday. Gain Therapeutics has a twelve month low of $1.11 and a twelve month high of $5.33. The business has a 50 day simple moving average of $1.98 and a 200-day simple moving average of $3.20. The company has a debt-to-equity ratio of 0.05, a current ratio of 2.77 and a quick ratio of 2.77.

Gain Therapeutics (NASDAQ:GANX) last issued its quarterly earnings results on Tuesday, May 14th. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.08. As a group, equities analysts expect that Gain Therapeutics will post -1.03 EPS for the current year.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.